TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04321252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KAE609
Description: * iv bolus administration over approximately 2 min for doses \< 75 mg (Cohorts A1, A2 and B1)~* iv infusion over approximately 10 min for doses ≥ 75 mg (Cohorts A3, A4, A5 and B2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KAE609
Description: * iv bolus administration over approximately 2 min for doses \< 75 mg (Cohorts A1, A2 and B1)~* iv infusion over approximately 10 min for doses ≥ 75 mg (Cohorts A3, A4, A5 and B2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KAE609
Description: * iv bolus administration over approximately 2 min for doses \< 75 mg (Cohorts A1, A2 and B1)~* iv infusion over approximately 10 min for doses ≥ 75 mg (Cohorts A3, A4, A5 and B2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KAE609
Description: * iv bolus administration over approximately 2 min for doses \< 75 mg (Cohorts A1, A2 and B1)~* iv infusion over approximately 10 min for doses ≥ 75 mg (Cohorts A3, A4, A5 and B2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KAE609
Description: * iv bolus administration over approximately 2 min for doses \< 75 mg (Cohorts A1, A2 and B1)~* iv infusion over approximately 10 min for doses ≥ 75 mg (Cohorts A3, A4, A5 and B2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KAE609
Description: * iv bolus administration over approximately 2 min for doses \< 75 mg (Cohorts A1, A2 and B1)~* iv infusion over approximately 10 min for doses ≥ 75 mg (Cohorts A3, A4, A5 and B2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KAE609
Description: * iv bolus administration over approximately 2 min for doses \< 75 mg (Cohorts A1, A2 and B1)~* iv infusion over approximately 10 min for doses ≥ 75 mg (Cohorts A3, A4, A5 and B2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matching placeo for iv administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matching placeo for iv administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matching placeo for iv administration
Study: NCT04049435

Intervention type: DEVICE
Intervention: Assessment of Horizontal Bone gain using patient specific titanium sheet: a novel protocol for treatment of horizontal deficiency in the anterior maxilla
Description: Assessment of Horizontal Bone gain using patient specific titanium sheet: a novel protocol for treatment of horizontal deficiency in the anterior maxilla
Study: NCT00065260

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Campath-1H
Description: Campath-1H IV 10 days. Adults:10mg/day (children:0.2mg/kg/day).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: r-ATG
Description: Rabbit ATG 3.5mg/kg/day for consecutive 5 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CsA
Description: CsA 10mg/kg/day orally twice daily for 6 months (15mg/kg/day for children under 12 yrs.
Study: NCT03161327

Intervention type: DEVICE
Group type: OTHER
Intervention: ABI using QuantaFlo™
Description: Perform Digital ABI:~* Will be performed by the nurse/medical assistant with training to perform this test~* The patient will be placed in the supine position, with the arms and legs at the same level as the heart, for a minimum of 5 minutes before measurement.~* The optical sensor (similar to a pulse oximeter) will be placed sequentially in the fingers of the hands and feet: Right and left hand fingers and then right and left feet toes.~* Usually each digit takes about 15 seconds to obtain a waveform~* At the end of 60 seconds, an automated digital ABI will be generated.~Clinical course: If based on Screening questionnaire and digital ABI, I. Patient is diagnosed with PAD- the referring physician and patient will receive a phone call about the same. He/ she will then be advised any further testing/ referral to IR clinic.~II. There is no evidence of PAD- no further action will be taken. The patient will be informed of the same.
Study: NCT00700336

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed, cisplatin and CBP501
Description: CBP501 25 mg/m2, Pemetrexed 500 mg/m2, cisplatin 75 mg/m2 CBP501 for injection is provided in single dose vials (20 mg) containing a sterile lyophilized powder comprising CBP501 peptide acetate salt (peptide base units). For administration, vial contents are reconstituted in 5% Dextrose Injection, USP, and added to a 100 mL IV bag of 5% Dextrose Injection, USP.~Pemetrexed: A commercial formulation of pemetrexed will be used, with reconstitution in 20mL 0.9% sodium chloride solution for injection, then dilution to 100mL.~Cisplatin: A commercial formulation will be used and will be diluted in 250 mL of normal saline for administration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pemetrexed and cisplatin
Description: Pemetrexed 500 mg/m2, cisplatin 75 mg/m2 Pemetrexed: A commercial formulation of pemetrexed will be used, with reconstitution in 20mL 0.9% sodium chloride solution for injection, then dilution to 100mL.~Cisplatin: A commercial formulation will be used and will be diluted in 250 mL of normal saline for administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed, cisplatin and CBP501, dose finding
Description: Dose level 1: CBP501 16 mg/m2, Pemetrexed 500 mg/m2, cisplatin 75 mg/m2 Dose level 2: CBP501 25 mg/m2, Pemetrexed 500 mg/m2, cisplatin 75 mg/m2 CBP501 for injection is provided in single dose vials (20 mg) containing a sterile lyophilized powder comprising CBP501 peptide acetate salt (peptide base units). For administration, vial contents are reconstituted in 5% Dextrose Injection, USP, and added to a 100 mL IV bag of 5% Dextrose Injection, USP.~Pemetrexed: A commercial formulation of pemetrexed will be used, with reconstitution in 20mL 0.9% sodium chloride solution for injection, then dilution to 100mL.~Cisplatin: A commercial formulation will be used and will be diluted in 250 mL of normal saline for administration.
Study: NCT01530698

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous dendritic cell vaccine
Description: Autologous monocyte-derived dendritic cells electroporated with mRNA encoding gp100 and tyrosinase (for antigen loading), active TLR4 and CD70 (for activation). Dendritic cells are vaccinated intranodally 3 times with biweekly intervals every 6 months, if no signs of progression, for a total of 9 vaccinations

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: autologous dendritic cell vaccine
Description: Autologous monocyte-derived dendritic cells electroporated with mRNA encoding gp100 and tyrosinase and matured with either cytokines or TLR ligands. Dendritic cells are vaccinated intranodally 3 times with biweekly intervals every 6 months, if no signs of progression, for a total of 9 vaccinations
Study: NCT00922220

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: stationary bike
Description: Participants rode a stationary bike for five minutes

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: lumbar extension exercise
Description: Participants performed four sets of fifteen lumbar extension exercises over fifteen minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: spinal manipulative therapy
Description: participants received spinal manipulative therapy to the low back
Study: NCT01538719

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rilonacept
Description: Patients randomized to active study drug will receive Rilonacept 320 mg subcutaneously (SQ) on day 0 and 160 mg SQ each week for 5 additional weeks

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients randomized to placebo will receive saline subcutaneously (SQ) on day 0 and each week for 5 additional weeks
Study: NCT04321252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matching placeo for iv administration
Study: NCT02514655

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nosten® pressure control (it's not an antibiotic, but simple device)
Description: One experimental group with the control of the cuff pressure by Nosten® device

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Manual pressure control
Description: One control group with the manual monitoring of the cuff pressure and inflation of the balloon
Study: NCT02009579

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nintedanib
Description: Subjects will receive 6 cycles of 3-weekly carboplatin (AUC 5) + paclitaxel (175 mg/m2) and Nintedanib 200 mg BID followed by Nintedanib maintenance until progression or for a total maximum duration of 120 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive 6 cycles of 3-weekly carboplatin (AUC 5) + paclitaxel (175 mg/m2) and placebo 200 mg BID followed by placebo maintenance until progression or for a total maximum duration of 120 weeks.
Study: NCT05204121

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elpida
Description: elsulfavirine, capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elpida
Description: elsulfavirine, capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elpida
Description: elsulfavirine, capsules
Study: NCT03732989

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Interactive toy prototype
Description: The interactive toy prototype takes the form of a hand-crafted plush toy, which was designed to support in-the-moment calming down strategies. The interaction relies on a number of sensors embedded in the 'creature' that register haptic interactions with the toy. In addition, a small vibration motor is used to indicate the creature's state by mimicking a frantic 'heartbeat'. If the creature is calming down in response to the child's touching of the sensors, the heartbeat slows down and eventually turns into happy purring (cf. paper linked below for more details about the design process).

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Non-interactive toy prototype
Description: This toy is the same as the interactive one, but with the interactivity features (haptic feedback) turned off so that it looks and feels like a regular, hand-crafted plush toy.
Study: NCT05455892

Intervention type: OTHER
Intervention: Clinical data collection during hospitalization in short geriatric units.
Description: Retrospective clinical data collection, at time of infection and 10 days later. Correlation between mortality and gravity. Identification of predictive mortality factors such as frailty, preexisting comorbidities, complications and treatments. Description of medical prescription evolutions.
Study: NCT05748002

Intervention type: OTHER
Intervention: Pentacam and Corvis ST
Description: morphological and biomechanical parameters of corneal were obtain by Pentacam and Corvis ST

Intervention type: OTHER
Intervention: Pentacam and Corvis ST
Description: morphological and biomechanical parameters of corneal were obtain by Pentacam and Corvis ST

Intervention type: OTHER
Intervention: Pentacam and Corvis ST
Description: morphological and biomechanical parameters of corneal were obtain by Pentacam and Corvis ST

Intervention type: OTHER
Intervention: Pentacam and Corvis ST
Description: morphological and biomechanical parameters of corneal were obtain by Pentacam and Corvis ST
Study: NCT04597749

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PSG
Description: In-lab sleep polysomnography test
Study: NCT02464852

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Head movements
Description: Participants will be asked to perform a series of movements of exploration of their maximum neck range of motion, including: flexion, extension, right and left lateral flexion, right and left axial rotation.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Activities of daily living (drinking, washing hand and eating)
Description: Patients will be asked to perform a series of activities of daily living (drinking, eating and washing hands).

Intervention type: DEVICE
Group type: OTHER
Intervention: Sheffield Support Snood

Intervention type: DEVICE
Group type: OTHER
Intervention: sEMG
Study: NCT02670525

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Leukemia Profiling
Description: Genetic profiling of leukemia cells will be performed and analyzed by an expert panel. Matched targeted therapy recommendation based on profiling results will be made if available. The recommendation, if available, will be communicated to the primary oncologist.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Leukemia Profiling
Description: Genetic profiling of leukemia cells will be performed and analyzed by an expert panel. Matched targeted therapy recommendation based on profiling results will be made if available. The recommendation, if available, will be communicated to the primary oncologist.
Study: NCT03365622

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: acetaminophen
Description: Active Intravenous doses will consist of a single 1,000mg/100 ml IV dose with contents of commercial vials transferred to an empty sterile IV bag.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Acetaminophen
Description: 500mg acetaminophen tablet ,2 capsules oral every six hours for 24 hours
Study: NCT04321252

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matching placeo for iv administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: matching placeo for iv administration
Study: NCT03365622

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo Intravenous doses will consist of 100ml of normal saline transferred to an empty sterile IV bag.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo, opaque capsules that have been filled with inert powder (lactose USP), 2 capsules oral every six hours for 24 hours
Study: NCT04313868

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GEN2 (HSV-Thymidine Kinase-m2 and hGM-CSF Genes)
Description: GEN2 is an investigational drug combining cytotoxic and immunotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GEN2 (HSV-Thymidine Kinase-m2 and hGM-CSF Genes)
Description: GEN2 is an investigational drug combining cytotoxic and immunotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GEN2 (HSV-Thymidine Kinase-m2 and hGM-CSF Genes)
Description: GEN2 is an investigational drug combining cytotoxic and immunotherapy.
Study: NCT02999477

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered in clinic every three weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered in clinic every three weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-Paclitaxel
Description: Nab-Paclitaxel will be administered in clinic every week.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-Paclitaxel
Description: Nab-Paclitaxel will be administered in clinic every week.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Biopsies for research purposes will be performed at three separate timepoints during treatment.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Biopsies for research purposes will be performed at three separate timepoints during treatment.
Study: NCT01827787

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin
Study: NCT04597749

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Home Sleep Apnea Test with FDA cleared devices
Description: In-lab HST test

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-Contact Screening App
Description: Non-Contact Sleep Apnea Screening Applications at bedside table to assess for sleep apnea.
Study: NCT00303667

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aldesleukin
Description: Administered subcutaneously (SQ) 9 million units every other day beginning Day -12 through -2 (evening of natural killer cell infusion) for a total of 6 doses.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aldesleukin
Description: Administered subcutaneously (SQ) 9 million units every other day beginning Day -12 through -2 (evening of natural killer cell infusion) for a total of 6 doses.
Study: NCT00303667

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: natural killer cells
Description: Infusion given on Day -12; The targeted infused cell dose of CD3- CD19- selected NK product is within the range of 2-3 x 10\^7 cells/kg.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: natural killer cells
Description: Infusion given on Day -12; The targeted infused cell dose of CD3- CD19- selected NK product is within the range of 2-3 x 10\^7 cells/kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Administered intravenously (IV) 50 mg/kg on Day -15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Administered intravenously (IV) 40 mg/m\^2 on Days -18 through -14

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic hematopoietic stem cell transplantation
Description: On day 0, patients will receive an allogeneic transplant using pool cells from the day -1 and day 0 PBSC which will be CD34+ selected as the donor graft. The graft will be infused over 15-60 minutes.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic hematopoietic stem cell transplantation
Description: On day 0, patients will receive an allogeneic transplant using pool cells from the day -1 and day 0 PBSC which will be CD34+ selected as the donor graft. The graft will be infused over 15-60 minutes.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total body irradiation
Description: Administered on Day -13, 200 cGy two times.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total body irradiation
Description: Administered on Day -13, 200 cGy two times.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Thymoglobulin
Description: intravenous (IV) 3 mg/kg on Day 0 (day of donor CD34 cell infusion)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Thymoglobulin
Description: intravenous (IV) 3 mg/kg on Day 0 (day of donor CD34 cell infusion)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporin A
Description: 1.5 mg/kg by mouth or intravenously for target dose range of 150-250; day -15 through day -8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporin A
Description: 1.5 mg/kg by mouth or intravenously for target dose range of 150-250; day -15 through day -8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Administered intravenously (IV) 50 mg/kg on Days -16 and -15

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Description: Administered intravenously (IV) 35 mg/m\^2 on Days -18 through -14
Study: NCT01163084

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Goserelin Acetate
Description: Given SC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Goserelin Acetate
Description: Given SC

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leuprolide Acetate
Description: Given IM

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leuprolide Acetate
Description: Given IM

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vismodegib
Description: Given PO
Study: NCT02331238

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Coaching Boys into Men program
Description: Coaching Boys into Men program consists of 60 minute training for high school coaches led by a violence prevention advocate to introduce coaches to the rational for Coaching Boys into Men and the Coaching Boys into Men Coaches Kit. The coaches use this Coaching Boys into Men toolkit to provide weekly discussions with their athletes (generally 10-15 minute mini-sessions) throughout their athletic season (11 weeks). Discussion topics include how to prevent disrespectful and harmful behaviors towards women and girls and how to promote healthy choices and relationships among youth.
Study: NCT00982891

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Opioid (morphine sulphate) in low dose
Description: individualized titration
Study: NCT02457884

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Temporal Group
Description: Visual Processing Training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Spatial Group
Description: Spatial visual span training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Combined Group
Description: Visual processing speed and spatial visual span training

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Group
Description: Leisure reading activities
Study: NCT03399994

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: device implantation during coronary angioplasty
Description: device implantation during coronary angioplasty

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: device implantation during coronary angioplasty
Description: device implantation during coronary angioplasty
Study: NCT03192852

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: dental bleaching
Description: dental bleaching can be achieved with light, light+ peroxide carbamide gel, or only with peroxide carbamide gel

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: dental bleaching
Description: dental bleaching can be achieved with light, light+ peroxide carbamide gel, or only with peroxide carbamide gel

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dental bleaching
Description: dental bleaching can be achieved with light, light+ peroxide carbamide gel, or only with peroxide carbamide gel

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dental bleaching
Description: dental bleaching can be achieved with light, light+ peroxide carbamide gel, or only with peroxide carbamide gel

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: dental bleaching
Description: dental bleaching can be achieved with light, light+ peroxide carbamide gel, or only with peroxide carbamide gel

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gingivoplasty
Description: gengivoplasty will be realized to in illuminated tissue an no illuminated tissue to morphometrically evaluate the tissue
Study: NCT01103479

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physician Intervention
Description: Physicians at these clinics will participate in 6 training sessions over the course of 3 1/2 years; training sessions relate to colorectal cancer (CRC) screening guidelines, communication skills, and health literacy training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physician and Patient Intervention
Description: Physicians at these clinics will participate in 6 training sessions over the course of 3 1/2 years; training sessions relate to colorectal cancer (CRC) screening guidelines, communication skills, and health literacy training; patients in this condition will also view an educational DVD on CRC and CRC screening